Description

Proactive: Prospective pioglitazone clinical trial in macrovascular events a macrovascular outcome study in type 2 diabetic patients comparing pioglitazone with placebo in addition to existing therapy.

Director of research: Tuomilehto Jaakko, Professor of Public Health

A macrovascular outcome study in type 2 diabetic patients comparing pioglitazone with placebo in addition to existing therapy.


The aim of the study is to evaluate the efficacy, safety and tolerability of tesaglitazar therapy when added to the therapy of patients with type 2 Diabetes poorly controlled on metformin alone Gallant 5.

StatusFinished
Effective start/end date01/01/200231/12/2015

Funding

  • Takeda: €135,965.00

Fields of Science

  • 3142 Public health care science, environmental and occupational health
  • pioglitazone
  • therapy
  • clinical trail
  • type 2 diabetes